000			04022nam a22003855i 4500
001			82347
003			ES-MaUEC
005			20230207040407.0
007			cr nn 008mamaa
008			150818s2015 gw | s |||| 0|eng d
020			_a9783319163048
024	7		_a10.1007/978-3-319-16304-8 _2doi
050		4	_aRC270 _b2015 EB
245	1	0	_aMolecular Oncology Testing for Solid Tumors : _bA Pragmatic Approach _cedited by Michael Ola Idowu, Catherine Isabelle Dumur, Carleton Theodore Garrett.
250			_a1st ed. 2015.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (IX, 742 páginas) _b142 ilustraciones, 139 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPart I. Overview of Basic Cellular Biology -- 1. Normal molecular biology and definition of terms -- 2. Pathologic changes: Chromosomes, genes, DNA, RNA and proteins -- 3. Standard nomenclature - introduction and brief overview -- Part II. Molecular Oncology Methodology -- 4. General principles of Oncology testing -- 5. Molecular methodologies -- 6. General principles of validating a molecular test -- Part III. Molecular testing in Solid Tumors -- 7. Lung and mediastinum -- 8. Breast -- 9. Head and neck (salivary glands) -- 10. Thyroid and parathyroid (endocrine) -- 11. Gastrointestinal and Pancreatobiliary -- 12. Soft tissue -- 13. Genitourinary system -- 14. Central Nervous System -- 15. Skin and adnexa -- 16. Common Hereditary Cancer Syndromes -- Part IV. The future is here -- 17. Application of next generation sequencing -- Part V. Quality Assurance and Regulatory affairs -- 18. Quality Assurance - pre-analytic, analytic and post-analytic -- 19. Regulatory affairs (including accreditation) -- 20. Coding and re-imbursement.
520	3		_aThis text is designed to present an up-to-date practical approach to molecular testing in an easy to understand format. Emphasis is placed on molecular testing for solid tumors, while underscoring the following: i) the crucial role of pathologists in ensuring specimen adequacy for molecular testing; ii) current molecular assays/platforms (including next-generation sequencing); iii) clinical utility and limitations of biomarkers to enable effective communication with clinicians; iv) the importance of quality assurance metrics to ensure accurate and reproducible results; v) pitfalls in test interpretation (that may lead to False Positive or False Negative interpretations); vi) importance of using standard nomenclature, including exercises on variant (mutation) description; vii) regulatory affairs, coding and reimbursement. The uniqueness of this text is the use of a standardized template for each of the molecular tests being discussed followed by a discussion of relevant quality assurance issues to ensure focused and efficient presentation of information. Molecular Oncology Testing for Solid Tumors will enable readers to easily understand the Ordering, Processing, Interpretation, Reporting and the clinical Application (OPIRA) process of molecular testing or biomarkers.
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
650		7	_aPatología _0 _2embne _9138489
650	2	7	_aPatología _0 _2embne _9138489
700	1		_aIdowu, Michael Ola _eeditor literario _995219 _0Local
700	1		_aDumur, Catherine Isabelle _eeditor literario _995220 _0Local
700	1		_aGarrett, Carleton Theodore _eeditor literario _995221 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-16304-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
907			_a.b12909877 _b10-10-17 _c10-02-16
988			_aSpringer_Medicine_2015
998			_am _a_alco _a_vill _b - - _cm _dz _e- _feng _ggw _h0
945			_aRC270 .M654 2015 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11577551 _z06-04-17
999			_c82347 _d82347 _x1